MarketCap
Facebook
X
TelegramZIOPHARM Oncology, Inc. EBITDA per Share | ZIOP
EBITDA per Share Jährlich ZIOPHARM Oncology, Inc.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0875 | - | 7.59 | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 7.59 | -0.0875 | 3.75 |
EBITDA per Share anderer Aktien in der Pharmaeinzelhändler
| Name | EBITDA per Share | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Trillium Therapeutics Inc.
TRIL
|
0.0792 | - | - | $ 1.94 B |  Canada |
 |
Urovant Sciences Ltd.
UROV
|
36.6 | - | - | $ 532 M |  Britain |
 |
Acceleron Pharma Inc.
XLRN
|
-0.413 | - | - | $ 10.9 B |  USA |
 |
Zealand Pharma A/S
ZEAL
|
-24.4 | - | 0.52 % | $ 821 M |  Danmark |
 |
Zogenix, Inc.
ZGNX
|
-0.792 | - | -4.97 % | $ 664 M | USA |
 |
Yunhong International
ZGYH
|
-0.792 | - | 0.10 % | $ 92.2 M |  China |
 |
Xenon Pharmaceuticals
XENE
|
-4.68 | $ 41.4 | 2.35 % | $ 3.28 B | Canada |
 |
Leap Therapeutics
LPTX
|
-0.62 | - | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
-4.11 | $ 31.45 | 2.08 % | $ 1.62 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
-11.7 | $ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
0.84 | $ 12.67 | -0.98 % | $ 3.02 B | USA |
 |
Cortexyme
CRTX
|
-1.16 | - | -1.05 % | $ 67.1 M | USA |
 |
Burford Capital Limited
BUR
|
1.06 | $ 3.66 | -1.35 % | $ 802 M | Britain |
 |
Daré Bioscience
DARE
|
-1.07 | $ 0.69 | 1.75 % | $ 7.71 M | USA |
 |
Fate Therapeutics
FATE
|
-1.13 | $ 1.78 | -8.51 % | $ 211 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-1.44 | $ 16.05 | -2.85 % | $ 217 M | USA |
 |
Halozyme Therapeutics
HALO
|
4.01 | $ 103.0 | 0.08 % | $ 12.3 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
-0.03 | $ 15.34 | 0.1 % | $ 13.2 B | China |
 |
Aptorum Group Limited
APM
|
0.05 | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
-0.33 | $ 0.78 | -1.89 % | $ 81.2 M | USA |
 |
Kodiak Sciences
KOD
|
-4.06 | $ 108.01 | 0.85 % | $ 5.75 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
-8.27 K | $ 0.02 | -54.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
-0.71 | - | 5743.5 % | $ 69.7 M | Canada |
 |
BioAtla
BCAB
|
-1 | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
2.11 | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
-2.59 | $ 25.32 | -3.78 % | $ 1.22 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
0.16 | $ 13.91 | 1.9 % | $ 1.24 B | USA |
 |
ARCA biopharma
ABIO
|
-2.5 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-0.67 | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
-517 | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-3.37 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-2.68 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-1.99 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-3.02 | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
0.45 | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-23.7 | - | - | $ 269 M | USA |
 |
AVROBIO
AVRO
|
-4.51 | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
12.6 | - | - | $ 96.9 B | Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1.05 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
0.42 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
-3.29 K | $ 0.39 | 9.06 % | $ 28.6 K | USA |
 |
Bio-Path Holdings
BPTH
|
-4.97 | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-3.59 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
0.21 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-2.08 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-3.85 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-3.85 | - | -4.36 % | $ 27 M | USA |